Today we announce the closing of a €3.3M funding round. The round includes continued support from existing investors, Voima Ventures and Eir Ventures, along with new investor Impilo Partners Invest.
The timing of this investment reflects a broader shift in biopharma towards data-driven and continuous manufacturing. The investment gives us additional resources to accelerate our technological development and commercial expansion in a global market.
Sofia Håkansson Buch, CEO, comments:
This capital injection provides us with the resources to significantly accelerate both our technology development and our commercial expansion. We are now well-positioned to scale the Auga™ platform, strengthen our presence in key markets, and bring real-time bioprocess monitoring to a broader range of customers worldwide.
